6032 related articles for article (PubMed ID: 2802931)
1. [Structure-activity relations of antineoplastic platinum II and platinum IV coordination compounds].
Gutsche W; Baumgart J; Schröer HP
Arch Geschwulstforsch; 1989; 59(4):233-8. PubMed ID: 2802931
[TBL] [Abstract][Full Text] [Related]
2. In vivo and in vitro effectivity of some platinum complexes.
Balázová E; Hrubisko M; Ujházy V
Neoplasma; 1984; 31(6):641-7. PubMed ID: 6395026
[TBL] [Abstract][Full Text] [Related]
3. [Acute and subacute toxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in laboratory rodents].
Härtl A; Güttner J; Horn U; Jelinek F; Stöckel U; Schröer HP; Hoffmann H
Arch Geschwulstforsch; 1989; 59(4):239-44. PubMed ID: 2640563
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antitumor activity of a new cis-diammineplatinum (II) complex containing procaine hydrochloride.
Cafaggi S; Esposito M; Parodi B; Vannozzi MO; Viale M; Pellecchia C; Fulco RA; Merlo F; Zicca A; Cadoni A
Anticancer Res; 1992; 12(6B):2285-92. PubMed ID: 1295476
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effectivity of two diaminocyclohexane Pt-complexes.
Balázová E; Hrubisko M; Ujházy V
Neoplasma; 1985; 32(5):537-42. PubMed ID: 4069288
[TBL] [Abstract][Full Text] [Related]
6. [Nephrotoxicity and myelotoxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in rats].
Horn U; Härtl A; Neuhaus G; Stöckel U; Schröer HP; Hoffmann H
Arch Geschwulstforsch; 1989; 59(4):245-50. PubMed ID: 2802932
[TBL] [Abstract][Full Text] [Related]
7. Cycloplatam and oxoplatin--the new antitumor platinum compounds of the second generation.
Presnov MA; Konovalova AL
Arch Geschwulstforsch; 1988; 58(1):43-9. PubMed ID: 3285804
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data.
Tashiro T; Kawada Y; Sakurai Y; Kidani Y
Biomed Pharmacother; 1989; 43(4):251-60. PubMed ID: 2790145
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
[TBL] [Abstract][Full Text] [Related]
10. Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes.
Khokhar AR; al-Baker S; Shamsuddin S; Siddik ZH
J Med Chem; 1997 Jan; 40(1):112-6. PubMed ID: 9016335
[TBL] [Abstract][Full Text] [Related]
11. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
[TBL] [Abstract][Full Text] [Related]
12. Comparative antitumor studies on platinum(II) and platinum(IV) complexes containing 1,2-diaminocyclohexane.
Vollano JF; Al-Baker S; Dabrowiak JC; Schurig JE
J Med Chem; 1987 Apr; 30(4):716-9. PubMed ID: 3560163
[TBL] [Abstract][Full Text] [Related]
13. Effect of treatment schedule on antitumor activity of glycolate-0,0'-diammineplatinum(II), a new platinum derivative: comparison with cis-diamminedichloroplatinum(II).
Suzumura Y; Kato T; Ueda R; Ota K
Anticancer Res; 1989; 9(4):1083-8. PubMed ID: 2817790
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane.
Anderson WK; Quagliato DA; Haugwitz RD; Narayanan VL; Wolpert-DeFilippes MK
Cancer Treat Rep; 1986 Aug; 70(8):997-1002. PubMed ID: 3731155
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of four polymer bound trans-1,2-diaminocyclohexaneplatinum(II)-4-carboxyphtalate complexes tested in different model systems.
Balázová E; Hrubisko M; Drobník J; Ujházy V
Neoplasma; 1986; 33(6):665-70. PubMed ID: 3808121
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance induction and cross-resistance studies with Pt-complexes.
Hrubisko M; Balázová E; Ujházy V
Neoplasma; 1984; 31(6):649-53. PubMed ID: 6542968
[TBL] [Abstract][Full Text] [Related]
18. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and cross-resistance studies with Pt-ascorbato complexes.
Hrubisko M; Balázová E; Kiss F; Kovácová J; Ujházy V
Neoplasma; 1989; 36(6):651-7. PubMed ID: 2615869
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin.
Kobayashi H; Takemura Y; Miyachi H; Ogawa T
Invest New Drugs; 1991 Nov; 9(4):313-9. PubMed ID: 1804804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]